血管紧张素转换酶抑制剂的临床评价与治疗监护  

Clinical Evaluation and Pharmaceutical Cure of Angiotesion Converting Enzyme Inhibitors

作　　者：张石革[1] 马国辉[1] 

机构地区：[1]北京大学北京积水潭医院,北京市100035

出　　处：《中国医院用药评价与分析》2010年第2期100-103,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:阐述血管紧张素转换酶抑制剂的研究进展和临床应用,评价其疗效与安全性。方式:采用近期中外专业文献综述方式。结果及结论:血管紧张素转换酶抑制剂在近年来进展迅猛,已成为治疗心血管疾病的基本药物之一,尤在对抗高血压上效果突出,在防治高血压及避免靶器官的损害方面具有广阔的应用前景,已被多项应用循证医学方法的临床研究所证实;但应监护其在治疗中的各种风险和问题。OBJECTIVE：To summarize the aspect of clinical usage and research progress on the angiotesion converting enzyme inhibitors（ACEI）,evaluete clinical efficacy and safety. METHODS：To collecte medical literatures in recent years at home and abroad.RESULTS CONCLUTION：Advance in angiotesion converting enzyme inhibitors has been swiftly in recent years,has already become one of the basic drugs for the treatment of cardiovascular disease,especially for the usage of antihypertension.it plays an important roles in treatment of hypertension and avoid damage of target organ,the results has been confirmend by the follow the evidence of clinical trial. But,watch attentively the treatment problem in pharmaceutical cure.

关 键 词：血管紧张素转换酶抑制剂 高血压 临床评价 药学监护 

分 类 号：R972.4[医药卫生—药品]